The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program

Early Breast Cancer ◽

Safety Data ◽

Metastatic Breast ◽

Pooled Analysis ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Abstract P4-14-12: Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

10.1158/1538-7445.sabcs15-p4-14-12 ◽

2016 ◽

Cited By ~ 2

Author(s):

N Woodward ◽

RH De Boer ◽

A Redfern ◽

M White ◽

J Young ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies

Annals of Oncology ◽

10.1093/annonc/mdw364.66 ◽

2016 ◽

Vol 27 ◽

pp. vi63

Author(s):

X. Pivot ◽

C. Poole ◽

M. Martín ◽

J. Gligorov ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Phase Iiib ◽

Cancer Studies

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

Investigational New Drugs ◽

10.1007/s10637-008-9166-8 ◽

2008 ◽

Vol 27 (2) ◽

pp. 166-172 ◽

Cited By ~ 11

Author(s):

G. Schilling ◽

M. Bruweleit ◽

N. Harbeck ◽

C. Thomssen ◽

K. Becker ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1028 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1028-1028 ◽

Cited By ~ 7

Author(s):

Binghe Xu ◽

Jiayu Wang ◽

Qingyuan Zhang ◽

Yunjiang Liu ◽

Ji Feng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Ib ◽

Multicenter Phase

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.02.008 ◽

2019 ◽

Vol 19 (3) ◽

pp. 216-224

Author(s):

Natasha Woodward ◽

Richard H. De Boer ◽

Andrew Redfern ◽

Michelle White ◽

Jennifer Young ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Open Label Phase

Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study

The Breast ◽

10.1016/s0960-9776(17)30116-9 ◽

2017 ◽

Vol 32 ◽

pp. S27

Author(s):

S. Talayeva ◽

D. Kaidarova ◽

E. Zhavrid ◽

A. Prokharau ◽

N. Antonenkova ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

European Journal of Breast Health ◽

10.4274/ejbh.galenos.2021.2021-9-9 ◽

2022 ◽

Vol 18 (1) ◽

pp. 63-73

Author(s):

İrfan Cicin ◽

Mohammed Oukkal ◽

Hassen Mahfouf ◽

Amel Mezlini ◽

Blaha Larbaoui ◽

...

Keyword(s):

Breast Cancer ◽

Patient Satisfaction ◽

Early Breast Cancer ◽

Subcutaneous Administration ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Abstract P4-21-31: Updated safety results from the first multicenter, open-label, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

10.1158/1538-7445.sabcs16-p4-21-31 ◽

2017 ◽

Cited By ~ 3

Author(s):

N Woodward ◽

RH De Boer ◽

A Redfern ◽

M White ◽

W Roberts ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Open Label Phase

Abstract OT3-1-03: An open-label, multicentre, phase IIIb study with intravenous administration of pertuzumab, subcutaneous trastuzumab, and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

10.1158/1538-7445.sabcs14-ot3-1-03 ◽

2015 ◽

Cited By ~ 1

Author(s):

Natasha Woodward ◽

Richard H De Boer ◽

Andrew Redfern ◽

Vita Von Neumann-Cosel ◽

Ronelle M Heath ◽

...

Keyword(s):

Breast Cancer ◽

Intravenous Administration ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30702-6 ◽

2021 ◽

Vol 22 (3) ◽

pp. 351-360

Author(s):

Binghe Xu ◽

Min Yan ◽

Fei Ma ◽

Xichun Hu ◽

Jifeng Feng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled